{"title":"Relationship Between Frailty and Drug Burden Index in Older Hospitalized Patients.","authors":"Yukako Morisaki, Misuzu Takashima, Ayako Maeda-Minami, Sayaka Izumi, Masanori Suzuki, Ryohkan Funakoshi, Yasunari Mano","doi":"10.21873/invivo.13971","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>In a super-aging society, understanding the prescription status of drug burden index (DBI) drugs that have anticholinergic and sedative effects in patients with frailty to consider proper medical intervention and promote appropriate drug use for older adults is important. This study evaluated the association between frailty and the use of DBI drugs in older hospitalized patients using hospital electronic medical records.</p><p><strong>Patients and methods: </strong>This cross-sectional study included patients admitted to the Kameda Medical Center between October 1, 2016 and October 31, 2017. Patients with a Barthel Index of <90 or Mini-Mental State Examination score of <18 or otherwise were classified into the frailty and non-frailty groups, respectively. DBI drugs fall into nine categories based on previous studies, and 162 drugs marketed in Japan were included. Patients using DBI drugs were considered DBI drug users; otherwise, patients were considered DBI drug non-users. Comparisons of the DBI drug proportions in both groups were performed using logistic regression analysis while adjusting for patient background factors and calculating the adjusted odds ratios and 95% confidence intervals.</p><p><strong>Results: </strong>The proportion of DBI drug users was significantly lower in the frailty group compared to the non-frailty group (adjusted odds ratio=0.32, 95% confidence interval=0.24-0.42, <i>p</i><0.001).</p><p><strong>Conclusion: </strong>Hospitalized older patients with frailty in Japan may be associated with a lower risk of DBI drug use and may use drugs with caution. In clinical practice, drug treatment for older patients may be implemented in consideration of various patient backgrounds, including frailty.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1694-1792"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13971","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: In a super-aging society, understanding the prescription status of drug burden index (DBI) drugs that have anticholinergic and sedative effects in patients with frailty to consider proper medical intervention and promote appropriate drug use for older adults is important. This study evaluated the association between frailty and the use of DBI drugs in older hospitalized patients using hospital electronic medical records.
Patients and methods: This cross-sectional study included patients admitted to the Kameda Medical Center between October 1, 2016 and October 31, 2017. Patients with a Barthel Index of <90 or Mini-Mental State Examination score of <18 or otherwise were classified into the frailty and non-frailty groups, respectively. DBI drugs fall into nine categories based on previous studies, and 162 drugs marketed in Japan were included. Patients using DBI drugs were considered DBI drug users; otherwise, patients were considered DBI drug non-users. Comparisons of the DBI drug proportions in both groups were performed using logistic regression analysis while adjusting for patient background factors and calculating the adjusted odds ratios and 95% confidence intervals.
Results: The proportion of DBI drug users was significantly lower in the frailty group compared to the non-frailty group (adjusted odds ratio=0.32, 95% confidence interval=0.24-0.42, p<0.001).
Conclusion: Hospitalized older patients with frailty in Japan may be associated with a lower risk of DBI drug use and may use drugs with caution. In clinical practice, drug treatment for older patients may be implemented in consideration of various patient backgrounds, including frailty.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.